NYSEAMERICAN:ATNM Actinium Pharmaceuticals Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Actinium Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $5.03 -0.13 (-2.52%) (As of 06/28/2022 12:00 AM ET) Add Compare Share Today's Range$5.00▼$5.1850-Day Range N/A52-Week Range$4.41▼$10.30Volume154,742 shsAverage Volume513,038 shsMarket Capitalization$119.64 millionP/E RatioN/ADividend YieldN/APrice Target$31.67 ProfileAnalyst RatingsChartCompetitorsEarningsInsider TradesInstitutional OwnershipHeadlinesOptions ChainShort InterestSocial Media View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive ATNM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Actinium Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address ATNM Stock Forecast (MarketRank)Overall MarketRank™1.70 out of 5 starsAnalyst Opinion: 3.5Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 - 3.5 Analyst's Opinion Consensus RatingActinium Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $31.67, Actinium Pharmaceuticals has a forecasted upside of 529.6% from its current price of $5.03.Amount of Analyst CoverageActinium Pharmaceuticals has only been the subject of 1 research reports in the past 90 days. Previous Next 5.0 Community Rank Outperform VotesActinium Pharmaceuticals has received 353 “outperform” votes. (Add your “outperform” vote.)Underperform VotesActinium Pharmaceuticals has received 105 “underperform” votes. (Add your “underperform” vote.)Community SentimentActinium Pharmaceuticals has received 77.07% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Actinium Pharmaceuticals and other stocks. Vote “Outperform” if you believe ATNM will outperform the S&P 500 over the long term. Vote “Underperform” if you believe ATNM will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldActinium Pharmaceuticals does not currently pay a dividend.Dividend GrowthActinium Pharmaceuticals does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Actinium Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 1.30% of the stock of Actinium Pharmaceuticals is held by insiders.Percentage Held by InstitutionsOnly 8.63% of the stock of Actinium Pharmaceuticals is held by institutions. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Actinium Pharmaceuticals are expected to decrease in the coming year, from ($1.14) to ($1.36) per share.Price to Book Value per Share RatioActinium Pharmaceuticals has a P/B Ratio of 1.44. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Actinium Pharmaceuticals (NYSEAMERICAN:ATNM)Actinium Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for bone marrow transplant (BMT) or a type of cellular therapy, and for other adoptive cell therapies. Its lead product candidate, I-131 apamistamab (Iomab-B) that is in a pivotal Phase III clinical trial for elderly relapsed or refractory acute myeloid leukemia trial for BMT conditioning; and a Phase I study with a CD19- targeted CAR T-cell therapy with memorial sloan kettering cancer center. The company also offers clinical and preclinical development programs that utilize multiple isotopes, including Actinium-225, Iodine-131, and Lutetium-177 directed at multiple validated cancer targets, including CD45, CD33, CD38, CD47, HER2, and HER3 for targeted conditioning prior to cell and gene therapies, such as bone marrow transplant and cancer therapeutics as single agents or in combination with other therapeutic modalities. It has collaboration with Astellas Pharma, Inc. to develop theranostics for solid tumor indications; EpicentRx, Inc that focuses on a novel CD47 immunotherapy targeted radiotherapy; and AVEO Oncology that focuses on developing a HER3 targeting ARC for solid tumors. The company was incorporated in 2000 and is based in New York, New York.Read More ATNM Stock News HeadlinesJune 9, 2022 | americanbankingnews.comActinium Pharmaceuticals (NYSEAMERICAN:ATNM) Downgraded by Zacks Investment Research to HoldMay 19, 2022 | finance.yahoo.comHas Alkermes (ALKS) Outpaced Other Medical Stocks This Year?April 25, 2022 | nasdaq.comActinium: All Patients Receiving Iomab-B Able To Proceed To Bone Marrow Transplant In Phase 3 TrialApril 25, 2022 | finance.yahoo.comActinium Pharmaceuticals, Inc. Announces 82% of Control Arm Patients Did Not Receive a Bone Marrow Transplant by Conventional Means but 100% of Patients who Received Iomab-B, Including Crossover Patients, in the Phase 3 SIERRA Trial Successfully Engrafted at the Transplantation & Cellular Therapy Tandem Meetings of ASTCT and CIBMTRApril 19, 2022 | finance.yahoo.comActinium Pharmaceuticals, Inc. to Highlight Iomab-B Pivotal Phase 3 SIERRA Trial Data at the Transplantation & Cellular Therapy Tandem Meetings of ASTCT and CIBMTRApril 13, 2022 | finance.yahoo.comActinium (ATNM) Up on Commercialization Deal With ImmedicaApril 12, 2022 | benzinga.comActinium Shares See Spike In Volume As Hearing Traders Circulate William Blair Note Showing ~$12.50 Price TargetApril 12, 2022 | msn.comWhy Actinium Pharmaceuticals Stock Is SurgingApril 12, 2022 | msn.comBenzinga's Daily Brief On Trending Tickers For April 12, 2022: Veru, Kohl's Corporation, BioCardia, And MoreApril 12, 2022 | nasdaq.comActinium Pharma In Deal With Immedica For Iomab-B; Sees Up To $452 Mln Milestone PaymentsApril 12, 2022 | seekingalpha.comActinium gains on agreement with Immedica Pharma for conditioning agentApril 12, 2022 | finance.yahoo.comActinium Pharmaceuticals, Inc. and Immedica Announce Commercialization Agreement for Iomab-B (131I apamistamab) in Europe, the Middle East and North AfricaApril 11, 2022 | finance.yahoo.comActinium Pharmaceuticals Presents Preclinical Data at AACR Showing HER3 Targeted Radiotherapy Combined with the CD47 Immunotherapy Magrolimab Increases the Anti-tumor EffectSee More Headlines Industry, Sector and Symbol Stock ExchangeNYSEAMERICAN Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNYSEAMERICAN:ATNM Previous SymbolAMEX:ATNM CUSIPN/A CIKN/A Webwww.actiniumpharmaceuticals.com Phone(646) 677-3870FaxN/AEmployees32Year FoundedN/ACompany Calendar Last Earnings5/13/2022Today6/28/2022Fiscal Year End12/31/2022Price Target and Rating Average Stock Price Forecast$31.67 High Stock Price Forecast$45.00 Low Stock Price Forecast$25.00 Forecasted Upside/Downside+529.6%Consensus RatingBuy Rating Score (0-4)3 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-22.22 million Net Margins-2,165.56% Pretax Margin-2,165.56% Return on Equity-32.48% Return on Assets-30.55% Debt Debt-to-Equity RatioN/A Current Ratio11.66 Quick Ratio19.87 Sales & Book Value Annual Sales$1.14 million Price / Sales104.95 Cash FlowN/A Price / Cash FlowN/A Book Value$3.50 per share Price / Book1.44Miscellaneous Outstanding Shares23,785,000Free Float21,745,000Market Cap$119.64 million OptionableOptionable Beta0.48 Actinium Pharmaceuticals Frequently Asked Questions Should I buy or sell Actinium Pharmaceuticals stock right now? 3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Actinium Pharmaceuticals in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Actinium Pharmaceuticals stock. View analyst ratings for Actinium Pharmaceuticals or view top-rated stocks. What is Actinium Pharmaceuticals' stock price forecast for 2022? 3 brokers have issued 12 month price targets for Actinium Pharmaceuticals' stock. Their ATNM stock forecasts range from $25.00 to $45.00. On average, they expect Actinium Pharmaceuticals' stock price to reach $31.67 in the next year. This suggests a possible upside of 529.6% from the stock's current price. View analysts' price targets for Actinium Pharmaceuticals or view top-rated stocks among Wall Street analysts. How has Actinium Pharmaceuticals' stock price performed in 2022? Actinium Pharmaceuticals' stock was trading at $6.05 at the beginning of 2022. Since then, ATNM stock has decreased by 16.9% and is now trading at $5.03. View the best growth stocks for 2022 here. Are investors shorting Actinium Pharmaceuticals? Actinium Pharmaceuticals saw a decrease in short interest in June. As of June 15th, there was short interest totaling 555,300 shares, a decrease of 23.9% from the May 31st total of 729,900 shares. Based on an average daily volume of 877,100 shares, the short-interest ratio is presently 0.6 days. View Actinium Pharmaceuticals' Short Interest. How were Actinium Pharmaceuticals' earnings last quarter? Actinium Pharmaceuticals, Inc. (NYSEAMERICAN:ATNM) issued its earnings results on Friday, May, 13th. The biotechnology company reported ($0.23) earnings per share for the quarter, beating the consensus estimate of ($0.31) by $0.08. The biotechnology company earned $0.94 million during the quarter. Actinium Pharmaceuticals had a negative net margin of 2,165.56% and a negative trailing twelve-month return on equity of 32.48%. View Actinium Pharmaceuticals' earnings history. When did Actinium Pharmaceuticals' stock split? How did Actinium Pharmaceuticals' stock split work? Actinium Pharmaceuticals shares reverse split on the morning of Tuesday, August 11th 2020. The 1-30 reverse split was announced on Monday, August 10th 2020. The number of shares owned by shareholders was adjusted after the closing bell on Monday, August 10th 2020. An investor that had 100 shares of Actinium Pharmaceuticals stock prior to the reverse split would have 3 shares after the split. Who are Actinium Pharmaceuticals' key executives? Actinium Pharmaceuticals' management team includes the following people: Mr. Sandesh C. Seth M.B.A., M.S., MBA, Chairman & CEO (Age 58, Pay $1.04M)Mr. Steven O'Loughlin BS, CFO & Corp. Sec. (Age 36, Pay $520k)Dr. Paul Diamond Esq., Ph.D., VP of Patent & Legal CounselDr. David Gould, Sr. VP of Corp. Devel. & Corp. AffairsDr. Bernie Cunningham, Exec. Director of Clinical Supply Chain & Logistics and CMC Project ManagementDr. Qing Liang, VP & Head of Radiation SciencesDr. Robert N. Daly M.S., Ph.D., VP & Head of Clinical OperationsDr. Mamata Gokhale, VP & Global Head of Regulatory AffairsDr. Avinash Desai M.D., Chief Medical OfficerDr. Arun Swaminathan Ph.D., Chief Bus. & Commercial Officer Who are some of Actinium Pharmaceuticals' key competitors? Some companies that are related to Actinium Pharmaceuticals include Calliditas Therapeutics AB (publ) (CALT), Mersana Therapeutics (MRSN), Celularity (CELU), COMPASS Pathways (CMPS), Centessa Pharmaceuticals (CNTA), Imago BioSciences (IMGO), Protagonist Therapeutics (PTGX), Cogent Biosciences (COGT), Entrada Therapeutics (TRDA), Nkarta (NKTX), Arcturus Therapeutics (ARCT), Esperion Therapeutics (ESPR), Arbutus Biopharma (ABUS), Tango Therapeutics (TNGX) and Intercept Pharmaceuticals (ICPT). View all of ATNM's competitors. What other stocks do shareholders of Actinium Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Actinium Pharmaceuticals investors own include OHR Pharmaceutical (OHRP), Fitbit (FIT), Global Ship Lease (GSL), Sorrento Therapeutics (SRNE), OPKO Health (OPK), Matinas BioPharma (MTNB), ADMA Biologics (ADMA), Gran Tierra Energy (GTE), Aeterna Zentaris (AEZS) and Bionano Genomics (BNGO). What is Actinium Pharmaceuticals' stock symbol? Actinium Pharmaceuticals trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "ATNM." Who are Actinium Pharmaceuticals' major shareholders? Actinium Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (3.88%), BlackRock Inc. (1.04%), Blair William & Co. IL (0.45%), State Street Corp (0.28%), Bank of America Corp DE (0.08%) and Group One Trading L.P. (0.00%). View institutional ownership trends for Actinium Pharmaceuticals. Which institutional investors are selling Actinium Pharmaceuticals stock? ATNM stock was sold by a variety of institutional investors in the last quarter, including ACT Capital Management LLC, Vanguard Group Inc., and Bank of America Corp DE. View insider buying and selling activity for Actinium Pharmaceuticals or view top insider-selling stocks. Which institutional investors are buying Actinium Pharmaceuticals stock? ATNM stock was bought by a variety of institutional investors in the last quarter, including Blair William & Co. IL, Simplex Trading LLC, Group One Trading L.P., State Street Corp, Cutler Group LP, and BlackRock Inc.. View insider buying and selling activity for Actinium Pharmaceuticals or or view top insider-buying stocks. How do I buy shares of Actinium Pharmaceuticals? Shares of ATNM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Actinium Pharmaceuticals' stock price today? One share of ATNM stock can currently be purchased for approximately $5.03. How much money does Actinium Pharmaceuticals make? Actinium Pharmaceuticals (NYSEAMERICAN:ATNM) has a market capitalization of $119.64 million and generates $1.14 million in revenue each year. How many employees does Actinium Pharmaceuticals have? Actinium Pharmaceuticals employs 32 workers across the globe. How can I contact Actinium Pharmaceuticals? Actinium Pharmaceuticals' mailing address is 275 Madison Avenue, 7Th Floor, NEW YORK, NY 10016, United States. The official website for Actinium Pharmaceuticals is www.actiniumpharmaceuticals.com. The biotechnology company can be reached via phone at (646) 677-3870 or via email at [email protected]. This page (NYSEAMERICAN:ATNM) was last updated on 6/28/2022 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. MarketBeat Resources Premium Research Tools MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools. Discover All Access Market Data and Calendars Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free. View Market Data Investing Education and Resources Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more. Financial Terms Details Here
